... -- AGTC to regain rights to five clinical and preclinical development programs; Biogen terminates collaboration agreement -- AGTC on schedule to advance its Phase 1/2 ...
... the injectable DMTs, in particular Teva's Copaxone, and moved towards Novartis' Gilenya, Biogen's Tysabri, and Genentech's Ocrevus. Following recent quarter-over-quarter increases, reported first-line Ocrevus use ...
December 6, 2018 •
AWP OTS (Original Text Service)
... Data * Positive interim analysis demonstrated proof-of-biology and proof-of-concept for BIIB067 * Biogen plans to advance BIIB067 to a pivotal clinical study * Biogen paid ...
... of penalties on Samsung BioLogics for alleged accounting missteps related to its Biogen-partnered joint venture, the company has launched a counterattack. Samsung BioLogics has filed ...
... Report Spinraza AVXS-101 CK2127107 RG7916 Olesoxime LMI070 Company Covered in this Report Biogen Inc. Roche AG Novartis AG Cytokinetics Inc Key Topics Covered: 1. Introduction ...
... programs to start clinical testing. Vir CEO George Scangos, who previously headed Biogen, said the trial “marks our transition to a clinical-stage company.” Despite the ...
